Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.

https://scrip.citeline.com/SC149962/Quick-Listen-Scrips-Five-MustKnow-Things

In this episode, HBW Insight dives into personalized wellness with Marni Allen, chief marketing officer at tailored supplements manufacturer Bioniq. Named as one of EY UK's 50 Women to Watch in 2022, Allen has over 20 years’ experience in consumer healthcare, and is now working with Bioniq to create the next generation of bespoke wellness products for consumers across the world. As well as its top tier at-home blood test-based service, Bioniq also offers an affordable questionnaire-based option, which leverages the power of AI to analyse users’ nutritional needs and provide unique supplement formulations in the post. Although personalized wellness is still somewhat niche, Allen suggests that AI-based models like Bioniq offer an attractive option for traditional consumer health companies looking to get into this fast-growing market.

Summary: 今回取り上げた記事はこちら

「MindMed Ready To Take LSD Therapy Into Phase III For Anxiety（MindMed、LSD療法を不安症治療の第III相治験へ）」

https://www.citeline.com/ja-jp/resources/mindmed-ready-to-take-lsd-therapy-into-phase-iii-for-anxiety

※全文の閲覧には情報の登録（無料）が必要です。

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

(英語版)

https://scrip.citeline.com/SC149912/MindMed-Ready-To-Take-LSD-Therapy-Into-Phase-III-For-Anxiety

※全文の閲覧には購読（有料）が必要です。

世界の製薬ビジネスメディアScrip（スクリップ）とは？

https://www.citeline.com/ja-jp/products-services/commercialization/scrip

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.

Links to the stories discussed are here: https://scrip.citeline.com/SC149924/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editor discuss Vanda’s decision to sue the FDA over the rejection of the Hetlioz jet lag indication (:30), Mark Cuban’s comments at a White House event that the federal government and others should stop doing business with the big three PBMs (11:50), and the cut in non-user fee dollars in the FY 2024 FDA appropriations bill (24:49).

More On These Topics From The Pink Sheet

Vanda Appeals FDA’s Denial Of Hetlioz Jet Lag Application As It Is Hit With CRL For Insomnia: https://pink.citeline.com/PS149914/Vanda-Appeals-FDAs-Denial-Of-Hetlioz-Jet-Lag-Application-As-It-Is-Hit-With-CRL-For-Insomnia

Mark Cuban: Pharma’s Secret Weapon In The Fight Against PBMs: https://pink.citeline.com/PS149899/Mark-Cuban-Pharmas-Secret-Weapon-In-The-Fight-Against-PBMs

Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities: https://pink.citeline.com/PS149897/Congress-Gives-US-FDA-Austere-Budget-But-Seeks-Boosts-On-Inspections-IT-And-ALS-Activities

2024년 글로벌 전문가들이 예측하는 치료영역의 발전은 무엇인 지에 대한 Scrip 기사를 요약한 내용입니다

https://scrip.citeline.com/SC149780/Scrip-AsksWhat-Does-2024-Hold-For-Biopharma-Part-6-Therapeutic-Area-Advances

In this episode, US regulatory reporter Hannah Daniel speaks to Ocutrx CEO Michael Freeman about augmented reality in medical products and their not-so-unique regulatory requirements.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.

https://scrip.citeline.com/SC149879/Quick-Listen-Scrips-Five-MustKnow-Things

iRhythm CEO Quentin Blackford returns to Medtech Insight’s Cardio Conversations podcast to talk about the launch of the company’s new Monitor long-term cardiac monitoring patch, the company's plans for the MCT market, and a lot more.